{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.142","upperLimit":"0.288","value":"0.208"},{"groupId":"OG001","lowerLimit":"0.121","upperLimit":"0.258","value":"0.182"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"description":"The definition of minor erythroid response: the mean hemoglobin is sustained 1.0 to 2.0 g/dL above the baseline value for a minimum of 8 weeks; or a 50% or greater decrease in 8-week red blood cell transfusion requirements compared to baseline.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21.","id":"OG000","title":"Arm A (Lenalidomide; Randomization)"},{"description":"Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.","id":"OG001","title":"Arm B (Lenalidomide + Epoetin Alfa; Randomization)"}],"paramType":"NUMBER","populationDescription":"Evaluable patients randomized to either arm A or arm B","reportingStatus":"POSTED","timeFrame":"Assessed every cycle during treatment and after completion of 16 weeks of treatment","title":"Proportion of Patients With Minor Erythroid Response","type":"SECONDARY","unitOfMeasure":"proportion of participants"}